Tony (Bizuo) Liu
Chief Executive Officer, Chief Financial Officer
Cellular Biomedicine Group
Mr. Liu formerly served as the Corporate Vice President at Alibaba Group responsible for Alibaba’s overseas investments. Since joining Alibaba in 2009, Tony held various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for the B2C global e-commerce platform. He was also Chief Financial Officer for HiChina, a subsidiary of Alibaba, a leading internet infrastructure service provider.
Prior to joining Alibaba, Tony spent 19 years at Microsoft Corporation where he served in a variety of finance leadership roles. He was the General Manager of Corporate Strategy looking after Microsoft’s China investment strategy and corporate strategic planning process. Tony was a key leader in the Microsoft corporate finance department during the 1990s as the Corporate Accounting Director. He was well recognized within Microsoft for driving an efficient worldwide finance consolidation, reporting, internal management accounting policy process, and showcased Microsoft’s best practices to many Fortune 500 companies in the U.S.
Mr. Liu obtained his Washington State CPA certificate in 1992. He had been serving as an Independent Director and Chairman of the Audit Committee for CBMG since March 2013 and was appointed as Chief Financial Officer in January 2014. He was appointed as Chief Executive Officer of the Company in February 2016.
Professor and Chairman of the Department of Basic Medical Sciences
School of Medicine
Dr. Xin Lin currently is a Professor and the Chairman of the Department of Basic Medical Sciences in Tsinghua University Medical School. Dr. Xin Lin obtained his Ph.D. degree from University of Texas Health Science Center in Houston in 1995. Following a postdoctoral training in UCSF/Gladstone Institutes in San Francisco, Dr. Lin started as an Assistant Professor in the State University of New York at Buffalo in 2000. In 2004 he was recruited to the University of Texas MD Anderson Cancer Center as an Associate Professor. Subsequently, he was promoted to Professor and then Endowed Professor in the University of Texas MD Anderson Cancer Center before his returning to China. He has been studying the molecular mechanism of signal transduction controlling lymphocyte activation, and their impacts on inflammation and anti-microbial and anti-cancer responses. Currently, his lab is developing therapeutic approaches using TCR-T/CAR-T cell methods to target cancer and viral infection.
Dr. Luk is the CEO at Neurophth Therapeutics, Inc. Prior to joining Neurophth, he has served as Senior Vice President and Chief Medical Officer at Shanghai Henlius Biotech, Inc., and he has also held executive roles at various MNCs such as Spark Therapeutics, Inc., Biogen Idec-Hemophilia (acquired by Sanofi), Bayer Schering Pharma LLC., Avigen, Inc.(acquired by Genzyme Corporation) and Tularik, Inc. (acquired by Amgen, Inc.) since 1998. Until 2003, his early researches were primarily investigating gene regulation and expression with the emphasis on rare diseases, oncological diseases, biologics and regenerative medicines. He served on the Clinical Design Committee for rare disease at the U.S. Food and Drug Administration focusing on adaptive clinical trial design to shorten drug development timeline between 2006 and 2009. Under his leadership in strategic drug development, he has won regulatory marketing approvals of 16 products in neurology, ophthalmology, gene/cell therapy, hematology and cancer therapy as of today.
Dr. Luk has published more than 85 book chapters, scientific and medical articles in highly regarded peer-reviewed journals, including New England Journal of Medicine, Nature, Cell, and Science, and is an inventor on over 10 patent applications. Dr. Luk holds an MBA from the Harvard Business School. He is ACRP-certified in clinical research and also received his Ph.D. in Neuroscience from the University of California San Francisco Medical School as well as bachelor’s degree in Molecular and Cell Biology from the University of California Berkeley in the United States.
Chief Technical Operation Officer
Dr. Su Xiao currently serves as the Chief Technical Operation Officer of Neurophth and she has served as a co-founder and board member of Neurophth since 2019. She has ten years of experience in translational sciences, early and late stage gene therapy development and manufacturing of biologics. Her goal is to make gene therapy affordable and accessible and she has primarily worked for organizations both large and small, including gene therapy development at Pfizer and National Institutes of Health and GMP manufacturing at Vigene Biosciences. She received her B.S. in Chemical Engineering from Tsinghua University and Ph.D. in Chemical and Biomolecular Engineering from the Johns Hopkins University.
Chairman Anlong Bio
Founder of Anlong Biology, Dr. Zhao Chunlin, 1985, the first undergraduate of Department of Biology, Tsinghua University. After graduating in 1990, he went to school in the United States. He received his Ph. D. in molecular biology from the University of Pittsburgh School of Medicine in 1996 and has been doing biological research in the United States for the past eight years. After getting an MBA from Chicago, he moved to business management, where he has more than 30 years of experience in research, multinational enterprises, entrepreneurship and investment. He has rich experience in the field of gene therapy and cooperation with European and American enterprises. Through years of Industry Experience, Dr. Zhao Chunlin believes that gene therapy uses viruses, DNA, its stability and portability is better than protein, gene therapy is a radical cure, and believes that as the technology matures, gene therapy could revolutionize medicine. With the maturity of Gene Biotechnology, Dr. Zhao Chunlin is determined to make his own contribution in the field of biomedicine, especially in gene therapy. At present, the strength of the R & D team is strong, with a large number of excellent doctors and returnees.
Product Manager Asia Cell Therapy
Chief Executive Officer
Dr. Ting He is the founder and CEO of Immunochina Pharmaceuticals. Dr. He received his B.S. in biology from Xiamen University and Ph.D. in cancer biology from Tsinghua University. With years of experience in basic research of cancer immunology, he is dedicated to develop innovative CAR-T therapy for treatment of cancer. He was awarded Beijing Nova program and Beijing Eagle Talents.
Chief Executive Officer
Dr. Min graduated from the University of California at Berkeley majoring in Molecular Biology in 1991 and held a Ph.D. in Molecular Biology from the University of California at Los Angeles in 1997. Dr. Min’s expertise includes biologics development from discovery to manufacturing as well as strategic planning and business development.
Dr. Min worked at Amgen in the U.S. as a principal scientist for over 10 years. He was in charge of biologics discovery and optimization, developing multiple protein therapeutics that are currently in clinical trials or on the market. After that, Dr. Min joined Samsung Advanced Institute of Technology. In that job, he worked as the Head of Antibody Engineering responsible for the development of a novel antibody-based therapeutic platform and as a leader for the oncology therapeutic development program. From 2010 to 2011, he carried out the responsibilities as Oncology Program Director in Biosimilar Group and Vice President of Strategic Business Development Group, focusing on antibody biosimilars development. From 2012 to 2017, he worked as Vice President of Process Team at Samsung Bioepis Co., Ltd. With responsibilities covering a full range of upstream and downstream process development, as well as tech transfer and GMP production. Just before joining GenScript, in 2018, Dr. Min worked at the Drug Substance Team of Samsung Bioepis Co, Ltd. as a senior Vice President, leading the process development of all biosimilars and new biologics in Samsung’s pipeline.
Senior Director of Analytical, Process Validation, QC, QA
Dr. Xinpo Jiang, Senior Director of Analytical Department/QA/QC at Legend Biotech, works on development of novel CAR T products in the pipeline. He was CMC Head leading LCAR-B38M CAR T product to clinical trial in China and US (collaborating with Janssen). He was Director of Pharmacology Department at GenScript for assay developments on biologicals and developed many cell-based and biochemical assays, oncology and antibody related functional assays. He received his Doctor of Philosophy from University of Minnesota, Twin Cities. He did a postdoctoral fellowship at Toronto Western Hospital, University of Toronto. Prior to his position at GenScript, Dr. Jiang was a research scientist at NeuroMed Pharmaceuticals. He published around 20 peer-reviewed journal articles and filed around ten patents.
President and Chief Scientific Officer
Guangdong Xiangxue Life Sciences
Yi Li, Ph.D. University of Leicester, UK, the National Distinguished Expert, Leading Talent of Guangdong Province, President and CSO of Guangdong Xiangxue Life Sciences, LTD, Principal Investigator of Center for Infection & Immunity at Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, PI at the State Key Laboratory of Respiratory Diseases. He has been engaged in the development of antibody and T cell receptor drugs in the UK for a long time. Representative papers have been published in Nature Biotechnology, Nature Medicine, JBC, Molecular Cancer Therapy, etc. He pioneered the application of phage display technology to the directed evolution of T cell receptors. He developed the world first human high-affinity soluble TCR, which the affinity for recognizing pHLA was increased by more than one million times as a key breakthrough in the field of TCR. Under his leadership his team has successfully developed a number of high-affinity TCRs at Immunocore in the UK, which has eventually been used in FDA-approved immunotherapy clinical research products. In 2012, he returned to China and led the establishment of China's first high-affinity TCR-mediated T cell therapy platform. The TCR-T product TAEST16001 injection developed by the Xiangxue team has obtained the first TCR-T IND approved by CDE of the National Medical Products Administration.
Founder and Chief Executive Officer
Nanjing CART Medical Technology
CAR-T therapy specialist, technical core personel in Carl June group at UPENN. Dr. Wang has long engaged in CAR design-evaluation, he is the participant in the first CAR-T drug R&D. He takes the lead in solid tumor CAR design and achieved recognition. He accomplished two solid tumor CAR-T patents together with Dr. Carl June and Dr. Michael Milone.
After returning to China, he finished the early exploration of donor CAR-T infusion for ALL patient and got succuess. Now Dr. Wang's team has been authorized two patents for invention. 25 patents application has been accepted by SIPO(State Intellectual Property Office). Multiple IIT clinical trials with Dr. Wang's CAR-T products have been carried out both in hematologic malignancies and solid tumors treatment.
VP Business Development APAC
As Vice President of Business Development APAC at Miltenyi Biotec, Hermann is responsible for Miltenyi’s strategic collaborations with Biotech and Pharma in Cell and Gene Therapy (CGT) in Asia. Joining Miltenyi Biotec in 2009, he was instrumental in building Miltenyi’s cell and gene therapy business as Business Area Manager, including the release of key ancillary materials and the T Cell Transduction Prodigy platform. In 2016 he led Miltenyi’s Australian business as Managing Director. Before joining Miltenyi, Hermann was responsible for the project management for early drug and monoclonal antibody development at MediGene Immunotherapies, Munich. He holds a doctoral degree from the University of Bonn and the Helmholtz Research Center Juelich for studies on bioprocess development of DCs and ACT in solid tumor indications. He continued similar studies at King’s College London (Guy’s Hospital) with Cancer Research UK.
Head of the Industrial Process Development Team
As the Head of the Industrial Process Development Team at Miltenyi Biotec, Silvio is responsible to provide automated Cell and Gene Therapy procedures on the CliniMACS Prodigy for industrial customers. Silvio has more than 10 years of R&D experience in various fields of cell biology, including Immunology, Regenerative Medicine and Pharmacology. After joining Miltenyi, Silvio has been coordinating custom-tailored development of automated processes for T-cell mediated Immunotherapy, Stem Cell Engineering and other innovative Cell and Gene Therapy approaches using the Miltenyi Biotec CliniMACS Prodigy platform. Silvio holds a Diploma degree in Biochemistry from the University of Bielefeld and a Doctoral degree in Biochemistry from the University of Kiel.
Vice President, General Manager, Cell Drug Business Unit
Shanghai Cell Therapy Group
Pete Gagnon is a widely respected global authority in the field of downstream processing. He is the author or more than 100 scientific publications and inventor on more than 100 awarded patents in the United States, Europe, and Asia. His expertise covers purification of monoclonal antibodies, virus particles, extra-cellular vesicles, plasmid DNA, and mRNA. He is currently Chief Scientific Officer at BIA Separations, a European manufacturer of specialized chromatography media for purification of gene therapy products.
Chief Medical Officer IASO Biotherapeutics
Dr. Wen (Maxwell) Wang currently is the Chief Medical Officer in IASO Biotherapeutics Co., Ltd. He obtained his M.D. degree in Wuerzburg University in Germany and Ph.D. degree from University of Aberdeen in UK and then did his postdoctoral training in at UConn Health Center in USA.
Dr. Wang has over 7 years of experience in Chinese Leading cell therapy companies including JW Therapeutics, Cellular Biomedicine Group (Nasdaq: CBMG) in clinical, preclinical, and translational development including CART cell and stem cell therapy. He held one of leading position in the 1st Chinese CD19-targeted CART cell and Mesenchymal Stem Cell INDs.
Before industry career, Dr. Wang worked as a Resident and Attending in Orthopedic Department in Shanghai TCM Hospital for 5 years.
Shenzhen Institute for Innovation and Translational Medicine
Dr. Mingjun Wang，Executive President of Shenzhen Institute for Innovation and Translational Medicine, received his MD from Anhui Medical University in China and his PhD degree in Cellular Immunology from the University of Copenhagen in Denmark in 2009, and finished his postdoctoral training in cancer immunology at Baylor College of Medicine in Houston of the United States. His research is focused on identification of cancer antigens and the development of T cell-based cancer immunotherapy using TIL, TCR-T cells or CAR-T cells for various types of malignancies. Dr. Mingjun Wang has published more than 30 peer-reviewed papers and three book chapters in the field of cancer immunology.
Regional Commercial GM-Asia Cell & Cene Therapy
• XIAOLIANG works with senior leadership teams of Cytiva in Asia Cell & Gene Therapy markets to develop profitable go-to-market growth strategies. With over 15 years successful commercial experiences in Pharmaceutical industry, XIAOLIANHG helps clients assess dynamics of their needs and grow their business further more.
• XIAOLIANG has worked in life science industry (IVD, Academia, Bio-Pharma, Cell & Gene Therapy) for around 20 years and brings a wealth of experience to every client engagement. His deep knowledge, networking and experience of Industry-Academia-Research platform has accelerated many small-/medium-size firms to scale up and go-to-market in past 10 years.
XIAOLIANG earned his Mini MBA and Diploma Leadership Development Program from China Europe International Business School, with honors, and his Bachelor of Science degree from ZheJiang University.
Dr. Zhang Yu is the president and CEO of Aeon Therapeutics Inc., a joint-venture biotech company established by Eureka Therapeutics Inc. and Vcanbio Cell&Gene Engineering Co.,Ltd. Prior to found Aeon, Dr. Zhang acted as assistant president and senior strategic planning expert in Vcanbio. Dr. Zhang received his B.S. in Bioengineering and M.S. in Biomedical Engineering from Beihang University, and Ph.D. in Stem Cell and Regenerative Medicine from Heinrich-Heine-Universität Düsseldorf in Germany. Before the industrial career, he worked in Rhine Forum, University of Applied Sciences Bonn-Rhein-Sieg, and was a visiting scholar in German Aerospace Center and University of Palermo. He is a member of German Society of Stem Cell, Chinese Society of Cell Biology, and reviewer of several journals, e.g. Current Stem Cell Research&Therapy. Dr. Zhang was the winner of “131 talent plan”and “Tianjin Green Card Plan”.
Dr. Biao Zheng graduated with a medical degree from Zhejiang University School of Medicine. He received his PhD in Immunology from King’s College, University of London. Dr. Zheng served at the faculty of University of Maryland School of Medicine and Duke University Medical Center 1996-1999. He has been a professor in the Department of Pathology and Immunology, Baylor College of Medicine since 1999. Dr. Zheng joined GlaxoSmithKline R&D Center in 2010 as the head of Immunological Discovery Sciences. He was the vice president of Global Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific, from 2015 to 2018, responsible for the innovative immunological drug pipeline in the region. He was the Chief Scientific Officer of Genfleet Therapeutics 2018-2020. Dr. Zheng recently joined Iaso Biotherapeutics as the Chief Scientific Officer.
Dr. Zheng is an experienced physician scientist, drug hunter, and professor with a demonstrated history working both in academia and pharmaceutical industry. He has more than thirty years of experience in biomedical research and drug discovery. He has published extensively in world top journals including Nature and Science. His major areas of research and development include autoimmune diseases, immuno-oncology, and novel vaccine development.
Chairman & CEO Wuhan Bio-Raid Biotech
Tong-Cun, Zhang, Ph.D, M.D; a distinguished professor in Hubei Province, is currently the Dean of College of Life Sciences and Health at Wuhan University of Science and Technology(WUST).
Dr. Zhang has got his Ph.D degree in 2000 from Institute of Biophysics, Chinese Academy of Sciences. Dr. Zhang was once honored with the of NRC Postdoctoral Fellowship Award in 2000-2003 in USA and then joined in UNC at Chapel Hill as assistant professor. Since 2012 he has taken a full-time professor and dean in WUST.
Dr. Zhang has aimed to the scientific research of the gene regulation, related to human diseases and development of biological drugs. In recent years, he has focus on CAR-T cell therapy for blood and solid cancers. His team has carried out novel CAR-T clinical trial in several hospitals and got excellent clinical effects and safety, which were published in Blood and Leukemia. CAR-T targeting to CD30 is trialed in clinical phase I.
Dr. Zhang has obtained several grants from The National Natural Science Foundation of China and ministry of Science and Technology, including National Key Research Program, 863 Programs, 973 Program. He has published over 100 theses in relevant research fields at high level scientific Journals. Novel patents for CAR-T cell-therapy over world has been obtained in his leading team.
Since he come back China, Dr. Zhang has been honored with local and national talent and outstanding titles. He was also awarded US-EPA's Scientific and Technological Achievement Award in 2003.
Dr. Liming Yang is the Co-founder and Chairman at Wyze Biotech Co., Ltd, a Hangzhou China based clinic stage company, engaged in the development and commercialization of novel allogeneic DNT (Double Negative T) cells and off-the-shelf cell immunotherapies to improve the lives of cancer patients and their overall survival by leveraging the clinically validated DNT cell technology. The first-in-class phase I clinic trial to relapsed AML patients after allo-HSCT has been finished in June 2020 with very promising clinic data. The IND application of RC1012 injection to r/r AML has recently been accepted by CDE of NMPA. Dr. Yang was associate director of product development in Stemgent and quality control manager in BD Biosciences Pharmingen, both based in San Diego, California, USA. He also worked previously as postdoctoral fellow at University of Toronto, Canada on DNT project and is one of the key inventors of DNT technology. Dr. Yang served as PI and associate professor when he worked in Medical School at Shanghai Jiaotong University in China. He received his M.D. from the Medical School at the Zhejiang University and finished his joint Ph.D. program in both Shanghai Jiaotong University in China and University of Toronto in Canada. Dr. Yang has published nearly 30 papers in peer-reviewed journals including first author in Nature Medicine and is an inventor on 5 patent applications in the field of DNT Technology.s
Vice President, Clinical Development CARsgen Therapeutics
Dr. Wei Wang is the Vice President of Clinical Development at CARsgen. She leads CAR-T and monoclonal antibodies China clinical development programs and manages medical affairs, clinical operation, biometrics and pharmacovigilance.
She has over a decade experiences in China and global clinical development programs in Merck, Novartis and Pfizer, managing team in clinical development, medical affairs and pharmacovigilance. Dr. Wei Wang worked as the practicing pediatric physician for 6 years in Xiangya Hospital of Central South University. She earned her Master degree in clinical medicine from Central South University, and the M.D. & Ph.D. degree from Fudan University.
Group leader for TruUCAR™ platform development Gracell Biotechnologies
Dr. Wang received her PhD in Immunology from Washington University in St. Louis, focusing on T cell signaling transduction and T cell engineering. During her Postdoc research in Scripps-Calibr and her work as senior scientist at Poseida Therapeutics, Dr. Wang participated and led the development of multiple autologous and allogeneic CAR-T programs using different platform technologies. She joint Gracell Biotechnologies in 2018 and had led the development of “off-the-shelf” CAR-T program since then.
Dr. Lyu Lulu obtained her Ph.D. in clinical medicine (internal medicine, hematology) in 2006. Prior to 2007, she mainly undertook the clinical and scientific research on hematopoietic and mesenchymal stem cells. In 2001, Dr. Lyu participated in the first umbilical cord blood transplantation in China for the treatment of childhood leukemia. She pioneered and established the domestic technology of isolating mesenchymal stem cells from the umbilical cord in 2004. In the following year, she continued her research on hematopoietic cell transplantation and mesenchymal stem cells at Westchester Medical Center of New York Medical College. Dr. Lyu published various papers in domestic and international journals. After joining a multinational pharmaceutical company in 2007, Dr. Lyu was engaged in the research and development of innovative drugs and the strategic planning for new products in the fields of hematology and oncology for more than a decade. With key appointments being held in multinational companies including Novartis, Genzyme, Roche, AstraZeneca, and Merck, she has garnered a wealth of experience in R&D and product life-cycle management in the areas of targeted drugs, immunotherapy, and cell therapy. In addition, she has played a vital role in the R&D, registration, and market expansion of ground-breaking products for treating cancers such as Gleevec®, Herceptin®, Tagrisso®, and Keytruda®. In June 2018, Dr. Lyu left the international pharmaceutical corporate world to become a trailblazer focusing on the development of innovative drugs domestically. As the current CEO of Juventas Cell Therapy Ltd., she is committed to promoting the clinical research of cell therapy and to pushing forward the industrialization thereof, thus creating world-leading products based on cell therapy.
Founder and CEO
Dr. Cheng Liu is the founder and CEO of Eureka Therapeutics. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a PhD in Molecular Cell Biology from the University of California, Berkeley.
President and Chief Executive Officer
Henry Ji, Ph.D., co-founded and has served as a director of Sorrento since January 2006, and as its Chief Executive Officer and President since September 2012. Dr. Ji served as Sorrento’s Chief Scientific Officer from November 2008 to September 2012 and as its Interim Chief Executive Officer from April 2011 to September 2012.
Dr. Ji served as VP of Sales and Business Development at CombiMatrix, and was responsible for strategic technology alliances. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as VP of Business Development at Stratagene (later acquired by Agilent Technologies), a biotechnology company. In 1997, Dr. Ji co-founded Stratagene Genomics, a wholly-owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer and Director from its founding until 1999.
Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. He held many executive positions in biotechnology and life sciences companies during his career.
Founder & Chief Scientific Officer
Hebei Senlang Biotech
Jianqiang Li is currently the Founder and Chief Science Officer of Hebei Senlang Biotech, a company focuses on the development and clinical translation of next generation cell therapy technology. Dr. Li obtained his PhD degree from University of Wuerzburg in Germany. He did his postdoctoral training at City of Hope and Fred Hutchinson CRC. His expertise covered the following fields: Gene modified adoptive T cell therapy; In vitro expansion and gene editing of Hematopoietic stem cells; Transplant Immunology.
Founder and Chairman
Dr. Lin Yang is currently a Distinguished Professor at the Cyrus Tang Hematology Center of Soochow University, China, and an adjunct professor of Department of Lymphoma and Myeloma at the MD Anderson Cancer Center, USA. Dr. Yang is the founder/chairman/chief scientific officer of PersonGen BioTherapeutics (Suzhou) Co., Ltd., and Chairman/CEO of PersonGen-Anke Cellular Therapeutics Co., Ltd. Dr. Yang received many awards, including Innovation and Entrepreneurship Talent of Jiangsu Province, Six Peak Talent of Jiangsu Province, Gusu Innovation and Entrepreneur Leading Talent, Pioneer of Suzhou Industrial Park Technology, Nanjing “321” Technology Leaders, Second Prize of China Innovation and Entrepreneurship Competition, and many other honorary titles and awards. He has published more than 70 research articles in recognized peer reviewed journals, such as Cancer Cell, Cancer Research, Oncogene, JBC, and Cancer Science, etc., which were all funded by international, national and provincial foundations.
As a principle investigator, Dr. Yang plays a major role in the immunotherapy of CAR-T cells and CAR-NK cells of China, and has obtained impressive achievements in the industrialization and clinical trials of CAR-T cell therapy. Among them, several clinical trials are the first-in human projects performed globally, including CAR-T cell therapy for T-cell acute lymphoblastic leukemia, and 4th generation CAR-T cell therapy for solid tumors. Led by Dr. Yang, PersonGen-Anke’s CD19-CAR-T product has been submitted to Chinese FDA and is being under the evaluation process which is expected an approval from CFDA within next few months.
Chief Scientific Officer
The Pregene Biopharma Company
As the Chief Scientific Officer in Shenzhen PREGENE Biopharma Company, Ltd, Dr. Zhang Jishuai graduated from Zhengzhou University, receiving a B.S. degree in clinical medicine. Then, he got his M.S. degree in molecular immunology in the Fourth Military Medical University, and Ph.D. in genetics in Beijing Institute of Biotechnology. After that, he obtained the postdoctoral training in the Hormel Institute in the University of Minnesota.
As an expert on tumor biology, Dr. Zhang once did detailed study on tumor gene function (including tumor initiation, differentiation and metastasis), about which he published over 20 papers. In 2016, he founded the PREGENE Company and acted as the Chief Scientific Officer, from which he began the research and development of CART drug. Having built a platform of “Nanobody discovery, CART research and drug development”, PREGENE is now mainly focused on CART therapy for hematologic tumors.
China Business Head
Dr. Zhu has over 10 years’ experience in drug development, clinical operation, financial investment and business development in healthcare area, especially in the field of cell therapies. He got his Ph.D in Immunology from Duke University Medical Center and B.S. in Genetics from Fudan University. Initially he committed himself as a scientist by serving the GSK China R&D Center to identify new drug targets for neuro-inflammation diseases. This helped him to further develop his career as a Principal Investigator in Xinhua Hospital in Shanghai working on the MIF soluble receptor. He joined Novartis as the new translational medicine department was founded and became the Clinical Trial Leader for Asia Pacific region. At that time, he led several global multi-center studies including one Gleevec Ph III Trial. Dr. Zhu started to explore his new career track in financial investment after he was awarded his MBA degree from Fudan University. He focused on new technology innovation and rising stars in the cell therapy area. Prior to joining T-Cure Bioscience, Dr. Zhu was the BD head of Hrain Biotech and in charge of the licensing and financing of this well-known CART company in China.
Deputy Director, Clinical Diagnostic Dept.
Director, Flow Cytometry Lab
Lu Daopei Medical Group
Hui Wang, MD, is the Deputy Director of the Clinical Diagnostic Department(vice chairman grade), and Director of Flow Cytometry Lab at the Ludaopei Medical Group, as well as Director, CEO, and CMO of Synarc Research Laboratory (Beijing) Ltd.
Dr. Wang graduated from the Peking University Health Science Center.
She completed internal medical residency at the Beijing Shijitan Hospital, followed by a fellowship in Hematology Institute at the People’s hospital. She then joined the faculty at Ludaopei Medical Group in 2008. She primary area of clinical research is the clinical diagnosis of flow cytometry. Having been worked in flow cytometry field for 18 years, She has signed more than 300,000 diagnostic reports of immunophenotyping and MRD detection, of which more than 40% coming from other hospitals around China.
She has taken part in writing 10 professional books, given nearly 600 professional oral presentations in 29 provinces of China(including Taiwan). She has hundreds of students from over 100 well-known hospitals, distributed in 26 provinces of China (including Taiwan).
The chairman of flow cytometry branch of professional committee on laboratory medicine, Chinese association of integrated traditional and western medicine
The vice chairman of blood & body fluid branch of Beijing Medical Laboratory Society
The standing committee member of hematology branch of Chinese non-public Medical Association
The standing committee member of Chinese flow cytometry Union
The member and special expert of lymphoma branch of Chinese Anti-cancer Association, flow cytometry branch of Chinese society of hematology and immunology, cell analysis special committee of Chinese society of bioengineering, and other societies.
Chief Operating Officer
Asclepius Technology Company Group
Dr. Jijun Yuan is co-founder and chief executive officer of Shanghai Genbase Biotechnology Co. Ltd, which was established in 2015 to focus on developing new therapeutic drugs, including cell therapies, gene therapies and therapeutic antibodies. Prior to that, Dr. Jijun Yuan spent six years at Shanghai Hengrui Pharmaceutical Co. as the associate director in charge of the biological division. He has been involved in more than 30 drug discovery programs, including oncology, diabetes and cardiovascular therapeutic drugs.
Dr. Jijun Yuan holds a PhD degree in molecular biology from Ohio State University and worked as postdoctoral researcher at University of California Los Angeles.
Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, Medical Director of The Cell and Gene Therapy Lab Children’s Hospital of Philadelphia (CHOP)
Stephan Grupp, MD PhD, is the Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, and Medical Director of The Cell and Gene Therapy Lab at the Children’s Hospital of Philadelphia (CHOP), as well as the Yetta Dietch Novotny Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine.
Dr. Grupp graduated from the University of Cincinnati after completing the MD/PhD program with a PhD in Immunology.
He completed pediatric residency at the Boston Children’s Hospital, followed by a fellowship in Pediatric Hematology/Oncology at the Dana Farber Cancer Institute and postdoctoral work in Immunology at Harvard University. He then joined the faculty at Harvard University until 1996, when he came to CHOP. His primary area of clinical research is the use of CAR T and other engineered cell therapies in relapsed pediatric cancers. He led all of the pediatric ALL trials of CTL019 (now approved as Kymriah), including the largest and most successful engineered T cell therapy clinical trial conducted to date (1, 2), as well as the global registration trial for CTL019 (3). As a result of this work, he presented the Clinical Perspective at the July 2018 FDA ODAC meeting, at which reviewers voted 10-0 for recommendation of approval for Kymriah in pediatric ALL. His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers. Dr. Grupp is a reviewer for several journals and the author of over 200 peer-reviewed journal articles, as well as numerous abstracts and book chapters.
Director, T Cell Engineering Laboratory, Center for Cellular Immunotherapies
University of Pennsylvania School of Medicine
Dr. Yangbing Zhao is an Associate Professor and the Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the University of Pennsylvania. He received an MD and PhD in Immunology from the Third Medical University in Chongqing, China. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells allogeneic bone marrow transplantation. For the next two years he was a research associate at Duke University Medical Center, where he worked on RNA transfected dendritic cell vaccines against cancers. In 2003, he joined Dr. Steven Rosenberg’s group as a senior research fellow at the Surgery Branch of the National Cancer Institute, where his research work directly led to clinical trials of treating cancer patients with T cells against Mart1, NY-ESO-1, Her2/Neu, CD19 (Yescarta) and VEGFR. He joined the faculty of the Department of Pathology and Laboratory Medicine, University of Pennsylvania in 2009 as the Director of TCEL. his research work at the University of Pennsylvania led to clinical trials to treat cancer patients with TCRT or CART against NY-ESO-1, CD19 (kymriah), Mesothelin, cMet, GD2 and CD123, as well as first in human CRISPR/CAS9 application in the world. Dr. Zhao has more than 20 years’ experiences in T cell engineering with over 50 publications and filed over 90 patents in the CART field. Dr. Zhao is the scientific co-founder of Tmunity Therapeutics.
Assistant Director, Michael G.Harris Cell Therapy and Cell Engineering Facility
Associate Laboratory Member, Department of Molecular Pharmacology Memorial Sloan Kettering Cancer Center
Dr. Wang was trained by Dr. Adolfo García-Sastre and received her Ph.D. in Biomedical Sciences from the Mount Sinai School of Medicine in NYC. She joined Dr. Peter Cresswell’s laboratory in the Department of Immunology at Yale University as a Howard Hughes Medical Institute fellow, and later as a Cancer Research Institute postdoctoral associate. Dr. Wang joined Memorial Sloan Kettering Cancer Center in 2007, and is currently an Associate Lab Member in Department of Molecular Pharmacology, and the Assistant Director of the Michael G Harris Cell Therapy and Cell Engineering Facility. Dr. Wang is in charge of the R&D, process development and manufacturing. She has overseen the successful manufacturing of all the CAR T cell products used in 13 phase I/II clinical trials as well as over 20 batches of cGMP grade viral vectors. She served in the translational science and product development committee in the American Society of Gene and Cell Therapy (ASGCT). She is currently a member for the National Heart, Lung and Blood Institute (NHLBI) independent external panel and a committee member for the Alliance of Regenerate Medicine (ARM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).
Yajin (Jenny) Ni
Senior Director, Process & Product Development, Technical Operations Allogene Therapeutics
Dr. Ni is Senior Director, Process & Product Development at Allogene Therapeutics, leading the company’s manufacturing process development activities for its pipeline of off-the-shelf CART candidates. During her tenure at Allogeneic Therapeutics and previously at Pfizer from 2015 to now, she has led her team to establish platform allogeneic CART manufacturing processes for enabling pipeline programs quickly advancing to early clinical testing using robust enough 1st generation process and transiting to late stage clinical & commercial manufacturing using more controlled 2nd generation automated & closed process. From 2000 to 2010 she held a senior technical role at VIRxSYS, where she conducted pioneering adaptive T cell therapy development work using lentiviral vector modified autologous CD4 T cells for HIV infection together with Dr. Carl June’s lab at the University of Pennsylvania. Through that work, they were 1st to bring lentiviral vector modified autologous adoptive T cell therapy into the clinic, and 1st to demonstrate feasibility of large scale GMP manufacturing of lentiviral vector and ex vivo expansion of gene-modified T cells in WAVE bioreactor. That work also accumulated a large set of patient safety data for lentiviral vector modified adaptive T cell therapy and laid down the groundwork for lentivector modified autologous CART therapy to be first tested in the clinic by Dr. Carl June’s lab. Dr. Ni earned a M.D. in internal medicine from the Kunming Medical College, P.R. China and received her Ph.D. in virology from the Kyoto University, Japan. She then conducted post-doctoral training in gene delivery at the NIH, USA before embarking on her gene & cell therapy product development career in both small biotech and big pharma.
Kerry L. Blanchard
Chief Executive Officer Everest Medicines
Dr. Blanchard’s career spans four decades in diverse leadership roles across North America and Asia. In February 2020 he was appointed as CEO of Everest Medicines after having served as Operating Partner at CBC Group, a healthcare private equity firm and one of the leading investors in Everest Medicines, since November 2019. Prior to CBC Group, he was Chief Science Officer at Innovent Biologics, where he oversaw the NDA preparation and submission for the company’s PD1 antibody, sintilimab, which was approved in late 2018 and launched in China in 2019 and led the partnership efforts with Incyte to develop three small molecule oncology assets for Greater China. Previously, Dr. Blanchard was the Senior Vice President of Lilly China Drug Development and External Innovation, where he built and led the development and medical affairs teams, who designed and implemented clinical plans for assets across all therapeutic areas. He also built and executed the company’s external partnership drug development portfolio model in China. He positioned Lilly to capitalize on the positive changes in the Chinese regulatory environment to expand the China innovation ecosystem. He built multiple successful partnerships that delivered new medicines to the China market including Innovent Biologics (sintilimab) and Chi-Med (fruquintinib). At Eli Lilly and Company he also initiated the project and led the team who delivered abemaciclib, the best in class cdk4/6 inhibitor, to the clinic.
His interests include discovering and developing medicines and the application of translational research principles to drug discovery. He was a co-founder and a member of the Board of Directors of the Asian Cancer Research Group, a not-for-profit company focused on the generation and dissemination of genetic and clinical data on cancers of importance in Asia. Dr. Blanchard received a BS degree in chemistry in 1977, a PhD in Biochemistry in 1982, and an MD in 1985 from Indiana University. He completed a residency in Internal Medicine and fellowships in Hematology and Medical Oncology at the Brigham and Women’s Hospital, the Dana Farber Cancer Institute, and Harvard Medical School in 1990. Dr. Blanchard was a Damon Runyon Fellow and a Fellow of the American Cancer Society. Prior to coming to Eli Lilly and Company in 2000, he was a tenured Professor of Medicine and Biochemistry & Molecular Biology at Louisiana State University Health Sciences Center in Shreveport, LA. He has had multiple global roles in Lilly Research Laboratories including Senior Clinical Research Physician in Program Phase Oncology, Chief Scientific Officer Cancer Discovery, Executive Director of Cancer Discovery & Lilly Systems Biology-Singapore, Chief Operating Officer/Vice-President of Discovery Research and Vice-President of Integrative Biology, and Vice-President of Tailored Therapeutics. He was a member of the board for Lilly China and Zymeworks INC and is a member of the board for The Confucius Institute in Indianapolis; he is also a member of the scientific advisory board for CBmed GmbH in Graz, Austria.
Vice President of Business Development Innovent Bio
Mr. Blake Salisbury is responsible for BD activities at Innovent, where he has lead the partnering efforts for cross border deals with Lilly, Roche, Coherus, Alector, Hanmi, MD Anderson, and others. He received his MBA from Thunderbird Graduate School of Global Management. He has 29 years of experience in pharma/biotech, primarily in business development (22 years), but also in sales, marketing, and pricing. Prior to joining Innovent, Blake spent almost 24 years with Eli Lilly and Company where he closed over 50 transactions of various types.
Chairman & CEO Chipscreen Biosciences
Dr. Xian-Ping Lu founded Shenzhen Chipscreen Biosciences, the leading drug discovery and development company in China focusing on innovative small molecular therapeutics, 19 years ago with a group of US-trained professionals. Previously he was Director of Research at Galderma R&D in Princeton until 2000, the year he became visiting professor at China’s State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University. He also participated in founding Galderma Research Inc. and Maxia Pharmaceuticals in San Diego around 1994.
Dr. Lu came to the US in 1989 for postgraduate fellowship study at the Department of Pharmacology, University of California in San Diego, followed by research at La Jolla Cancer Research Foundation (Burnham Institute). He obtained his Ph.D. in Molecular Biology and M.S. in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his B.S. degree in Biochemistry from Sichuan University.
With over 30 years of biomedical research and biotech/pharmaceutical experiences in various therapeutic areas, Dr. Lu is a skilled leader of diverse groups in global operating settings. He has published more than 100 peer-reviewed papers in prestigious journals including Nature, Science and The Lancet Oncology. He is the lead inventor of over 100 patented inventions in areas of small molecule therapeutics.
Dr. Qiu is the CEO of Qilu Regor Therapeutics, an innovative drug discovery company he founded together with a team of accomplished scientists and executives from top global pharma companies. Located in Shanghai, Boston and San Diego, Regor leverages world-class expertise in Computer Accelerated Rational Discovery (CARD) and efficient R&D ecosystems to accelerate the delivery of novel therapeutic agents with high unmet medical needs for patients in China and around the world.
Before returning to China in 2018, Dr. Qiu was Executive Director & Head of Structural & Molecular Sciences at Pfizer. He built and led a team of ~60 scientists with industry-leading expertise in structure-based drug design, computational sciences, and integrated molecular mode of action approaches. Prior to joining Pfizer in 2001, he was a member of GSK Global Target Evaluation Meeting and Novel Targets Committee. In 25 years in industry, he has contributed to 30 clinical candidates across diseases areas (inflammation & immunology, neurosciences, oncology, cardiovascular & metabolic, infectious & rare diseases) and therapeutic modalities (small molecule, ADC, biologics & vaccine). He discovered PCSK9 molecular mode of action that led to the industry-wide shift from seeking protease inhibitors to antibody therapies. He built the first cutting-edge cryo-EM lab in industry & New England, and delivered multiple clinical candidates using fragment-screening. He also served as President of New Drug Research for Qilu, one of the biggest pharmaceutical companies in China.
Dr. Qiu graduated from Peking University, obtained PhD at Michigan State, and completed executive trainings at Harvard Business School. He was an NIH Fellow and HHMI Research Associate at University of Washington in Seattle. He has trained 15 postdocs, served on expert review panels for National Institute of Health and other US funding agencies, and has been a member of Faculty of 1000 since 2004. He has >6000 citations (h-index 39) from over 60 publications, including in top journals such as Nature and Science.
Chief Executive Officer METiS Pharmaceuticals
Sr. Vice President and Head of Lilly China Drug Development & Medical Affairs Center (LCDDMAC) Eli Lilly
Education & Academic Career:
• Postdoctoral Research Follow,
Massachusetts General Hospital, Harvard Medical School
• M.D. ,Ph.D.
Shanghai Medical School, Fudan University
• June,2017 to present
Sr. Vice President, LCDDMAC, Eli Lilly China
• Sep, 2010 to June, 2017
Vice President in LCDDMAC, Eli Lilly China,
• Apr 2007 to Sep 2010
Oncology Medical Director of GlaxoSmithKline China/HK
• Sep. 2001 to Mar. 2007
Oncology Chief Clinical Research Physician, Eli Lilly China
Vice President and Head of MSD China R&D MSD Research Laboratories
Zhengqing Li is the Vice President and Head of MSD China R&D. In this position, he is responsible for the operation and strategic direction of MSD R&D Center in Beijing. As the China R&D head, Zhengqing leads a development team whose primary mission is to bring innovative medicines and vaccines effectively and efficiently to meet unmet medical needs of Chinese patients. In addition, Zhengqing plays the leadership role in building MSD global capabilities in China, and in establishing external collaborations with research institutes, professional societies and industry partners. Under his leadership over the past 8 years, the MSD China R&D Center has been growing dramatically with more than 1000 scientists with expertise across Clinical Research, Regulatory Affairs, Clinical Trial Operations, Pharmacovigilance, Project Management, Biostatistics, Epidemiology, and Data Management, etc.
Prior to joining MSD, Zhengqing took a number of leadership roles with Bristol-Myers Squibb (BMS) including the Head of Clinical Research, China R&D and Executive Director and Head of Oncology & Neuroscience, Global Biometric Sciences. Prior to joining BMS, Zhengqing also worked with Pfizer and Procter & Gamble Pharmaceutics with increasing responsibility in drug development.
Zhengqing has authored and co-authored more than 40 scientific and clinical trial methodology papers and abstracts. He has played leadership role in the development and approval of nearly 20 drugs in China and United States. Which including famous HPV vaccine GARDASIL and GARDASIL 9, chronic HCV drug ZEPATIER and key product of immunotherapy KEYTRUDA, etc.
Zhengqing was born and grew up in China. He received his undergraduate education at University of Science and Technology of China and his PhD degree from University of Wisconsin-Madison with major in Biostatistics. Upon completion of his PhD, Zhengqing took a faculty position in the School of Public Health at State University of New York.
Chief Medical Officer Elpiscience Biopharma
Dr. Chin’s career spans over 20 years of experience in medical oncology and clinical development in the pharmaceutical industry. In January 2020 he was appointed as CMO at Elpiscience Biopharma.
Prior to joining Elpiscience, Dr. Chin was a Senior Medical Director of immuno-oncology, Global Clinical Development at AstraZeneca. There, Dr. Chin provided leadership and expertise to enable new investment decisions in oncology therapeutic development, which involved the successful development of clinical strategy, determining the direction of regulatory interaction and coordination/execution of new clinical trials. Prior to his career at AstraZeneca, Dr. Chin was a Global GI Oncology Lead at Eli Lilly. He was involved in the transfer of cetuximab (Erbitux) full rights in North America from BMS to Lilly, led regulatory submission for Erbitux label updates, and fulfilled Erbitux post-marketing commitment.
Dr. Chin started his career as a medical oncologist and served as an assistant professor in the Division of Hematology/Oncology at the Medical University of South Carolina in Charleston. He was a clinical investigator with a special interest in cancer therapeutic development and correlative studies. Over his career, Dr. Chin has served as PI or Co-I in over 20 active clinical trials. He is currently a member of the executive committee for the Chinese American Hematology and Oncology Network, a non-profit organization focused on fostering exchange of medical information between United States and China in the fields of hematology and oncology.
Head of Biosciences
Adlai Nortye Biopharma
Nanhai He is the Head of Biosciences of Adlai Nortye who has over 15 years of experiences in research / target identification, and multidisciplinary background with past experience in biochemistry, immunology and metabolism. Dr. He received his Ph.D. in Molecular and Cell Biology from University of California, Berkeley, and finished his postdoctoral training at the Salk Institute for Biological Studies. Dr. He has published more than 20 papers his research field.
Vice President, Head of R&D and Chief Medical Officer
Dr. Xiaoning Guo is currently the vice President, Head of R&D and Chief Medical Officer of SciClone Pharmaceuticals co., LTD. He is fully responsible for R&D of pipeline drug candidates and life cycle management of post-market products. Dr. Guo graduated from Shanghai Institute of Materia Medica, Chinese Academy of Sciences with a PhD in pharmacology. Later, he went to the United States and worked as a research affiliate at Roswell Park Cancer Institute, a National Comprehensive Tumor Hospital and Cancer Center. In 2007, Dr. Guo came back to China and joined MNCs including Astrazeneca and Johnson & Johnson to in charge of translational medicine project, clinical Phase I to III project development and portfolio management. After a couple of years, Dr. Guo joined Covance as a senior Director, Clinical Drug Development Leader in Asia Pacific region, responsible for the development and implement of the global development strategy of the project. Dr. Guo has accumulated extensive experience in different stages of drug development from preclinical including biomarker research to translational medicine to clinical development. Before joining SciClone, Dr. Guo served as deputy General Manager and Chief Medical Officer of General Regeneratives, co., Ltd., responsible for clinical development and regulatory affairs department.
President and Chief Scientist Genor BioPharma
Visiting Professor Peking University
Previously, Dr. Zhou was Scientific Director at Amgen, Thousand Oaks, USA. His over 20-years experience of process development, multiple project management capacity in cGMP and non-GMP reproducible purification/production of protein/antibody therapeutics from FIH to CPD with depth knowledge of CHO clone selection, cell culture optimization, real time analytical assays, formulation and product specification for drug substances and drug products made Dr. Zhou many times as Project Process Team Leader/Project Team Leader/Cross Functional Core Investigation Teams Leaders at Amgen in the past.
Dr. Zhou has proven bio-industrial leadership in scientific innovation and technology evaluation, and is well known for implementation of membrane chromatography in mAb large-scale processing. Dr. Zhou has excellent reputation and an extended external network in the Process Development and or Process science peer community due to his extensive speaking and publication record including research articles, patents and book chapters in the Process Development and Process science field. Dr. Zhou has proven records for design space for process robustness and viral clearance in mAb production. Dr. Zhou was awarded as 2007 Amgen’s “Excellence n Science and Engineering” for his major achievement and leadership on photo-oxidation on monoclonal antibody yellowing, and selected by Amgen as a visiting professor teaching the GMP Master’s Degree Program at PKU, People’s Republic of CHINA since 2007.
Maggie Gu (Juanhong) is Vice President – R&D Shanghai Innovation Hub at Ipsen, a leading biopharmaceutical group dedicated to improving lives through innovative medicines in oncology, neuroscience and rare diseases.
Maggie has over 20 years of experience in clinical development, Medical affairs and Clinical Research operations in pharmaceutical indursry. Prior to Ipsen, she was Vice Present – Clinical research and operatnions in Junshi Bioscience, where she led and contributed to regulatory approval of the first China-developed PD-1 anti-body.
She started her career in the pharmaceutical industry as a Clinical Research Associate in Daiichi in 1997, and worked through the roles as Clinical Research Project Manager in MSD, Medical affairs manager in Fujisawa, Head of Clinical Operations and Therapeutic Area Medical Science Director at GlaxoSmithKline, as well as the Senior Director-Clinical Development in Clinical Operations at AstraZeneca.
She has successfully led development and registration activities of a series of innovative products in Oncology, Dermatology, Respiratory and other areas in China, including Tuoyi, Tagrisso, Botox, Avodart, Protopic etc. Prior to joining the pharmaceutical industry, Maggie worked in the Pediatric Research Institute,
Children’s Hospital affiliated to Shanghai Medical University. She holds a Master‘s degree in Pediatric Medicine from The Shanghai Medical University.
Xiang Yang Zhu
Chief Executive Officer Huaota Biopharm and Huabo Biopharm
Dr. Zhuis an expertin antibody drug discovery and process developmentwith more than 18 yearsof industrial experience. Hehas extensive experience in antibody drug discovery, process development, and manufacture facility construction. Dr. Zhu is the CEO for both Huaota Biopharm and Huabo Biopharm (members of Huahai Pharm), leads its global biotherapeutic research.Prior to join Huahai, he worked at Boehringer Ingelheim for more than 8 years in different function areas at multiple locations (Ridgefield, USA; Biberach, Germany; and Shanghai, China). He led andengaged inover 20 global BI biological research projects including current clinic Phase I-III projects and market products; Dr. Zhu obtained his PhDin microbiology and immunology fromtheUniversity of Illinois at Chicagoand has authored more than 20 publications in peer-reviewed journals.
Chief Executive Officer and Chief Scientific Officer Denovo BioPharma
Dr. Wen Luo has over 20 years of experience in biomedical research and industry including more than 15 years of experience in applying genomic technology in drug discovery and development. Prior to founding Denovo Biopharma, Dr. Luo managed the genomic group and provided bioinformatic support to a broad range of research projects across a number of therapeutic areas including oncology, hematology, inflammation and metabolic diseases at Ligand Pharmaceuticals. He was also responsible for developing clinical biomarkers for drugs in various stages of clinical trials. Before joining Ligand, he was a senior scientist for bioinformatics at Incyte Genomics, where he managed one of the largest proteomic databases, LifePro. He was also involved in discovering novel human genes and splice variants, and was the co-inventor of patents covering hundreds of novel genes derived from these findings. Prior to Incyte Genomics, he was a research scientist at Sugen, which had been acquired by Pharmacia, where he worked on drug target identification and validation for a number of novel kinases discovered at Sugen. Dr. Luo was a Howard Hughes Medical Institute post-doc fellow at the University of California, San Francisco, and received his Ph.D. in Molecular Biology and Biochemistry from Indiana University School of Medicine. Dr. Luo received pre-med training at Peking University and medical training at Peking Union Medical College.
General Manager, Head of SMO Services
Dr. Li is the founder, Chairman and CEO of HitGen Inc., and also a Fellow of the Royal Society of Chemistry and a Guest Professor of Sichuan University, etc. Dr. Li has over 30 years biopharmaceutical experience (at Protherics, AstraZeneca, HitGen), with senior scientific and leadership roles in early stage research; as well as experience in initiating and leading major collaboration, research and outsourcing programmes. Dr. Li held Global Director positions of Compound Sciences and Computational Sciences at AstraZeneca, which included molecular design, synthesis and screening. Dr. Li has published more than 30 papers and 20 authorized patents.
Since its foundation in 2012, HitGen has developed into one of the most influential companies in the field of novel drug discovery research centered on DNA Encoded Chemical Libraries (DELs). HitGen has established extensive international R&D collaboration and its own new drug pipelines. HitGen (688222.SH) became a listed company on the Science and Technology Innovation Board in Shanghai Stock Exchange on April 16, 2020.
Hequn Yin is currently CSO of Fosun Pharma. Prior to joining Fosun, Hequn was a VP of Pfizer Oncology R&D in California, USA. Before Pfizer, he spent nearly 20 years with Novartis in New Jersey, USA where he held positions of increasing responsibility from a Sr scientist to an Executive Director. Hequn also worked at Hoffmann-La Roche in New Jersey during 1997-98.
Hequn received a B.S. in chemistry from Peking (Beijing) University in 1985 and a M.S. from the Chinese Academy of Sciences in 1988. He earned a PhD degree in pharmacology from the University of Rochester, USA in 1995. Subsequently he conducted post-doctoral research in molecular biology & biochemistry at UC San Francisco, USA between 1995 and 1997. He also attend the eMBA program at Fairleigh Dickinson University in New Jersey.
SVP, Head of Business Development Zai Lab
Jonathan Wang is our head of business development since 2014. Prior to joining Zai Lab, Mr. Wang was an investment professional at OrbiMed, where he was responsible for China healthcare investment and portfolio management. From 2005 to 2011, Mr. Wang worked as a consultant at the Boston Consulting Group in China, where he specialized in pharmaceutical and healthcare engagements, assisting multinational and local companies with their China strategy. Previously, Mr. Wang also gained financial transactional experience at Goldman Sachs Investment Banking. Mr. Wang received a master of business administration in healthcare management from Wharton Business School.
Senior Director & Asia Emerging Science Lead (Shanghai), Asia Discovery Labs, Emerging Science & Innovation (ES&I)
Pfizer Worldwide Research & Development
Dr. Feng Bian is a Senior Director and Asia Emerging Science Lead in Pfizer Asia Discovery Labs (ADL) of Pfizer’s Worldwide Research and Development. She is responsible for cultivating strong and in-depth scientific relationships with Asia Academic and Life Science Communities with a primary focus on southern China regions to access emerging sciences, promising compounds, and breakthrough technologies.
Prior to ADL, Dr. Bian was a senior investigator in China Novartis Institutes for Biomedical Research and group head of liver pharmacology since 2014 in Shanghai. At Novartis, she was a project leader and managed liver disease pharmacology platform to deliver data packages for drug discovery projects. Before Novartis, she was a key scientist participated in setting up JnJ China research labs in 2012, and Associate Director of Biology to manage CROs and academic collaborations as well as internal R&D programs. Dr. Bian began her R&D career in Parke-Davis/Warner-Lambert in US as an in vivo pharmacologist in the Neuroscience Division, and later became a principle scientist in Pfizer’s Neurodegeneration and Psychotherapeutics Unit, contributing to programs like Lyrica®, discovery programs for Alzheimer’s disease, bipolar depression and dermal fibrosis. Dr. Bian has 20 years of expertise in small molecule and biologics drug discovery and her work has enabled NMEs to reach first in human. Dr. Bian received her Doctorate degree in Biochemistry from The Ohio State University and her Bachelor of Science degree from Nankai University at Tianjin, China.
Qun (Max) Dang
Corporate Vice President, President, CEO
CSPC, CSPC Shanghai Research Institute, InnovStone Therapeutics
Max received his BS from Jilin University with honors and earned a CGP national scholarship sponsored by the Chinese government; he obtained his Ph.D. in organic chemistry from Purdue University in 1992, joined Gensia (later became Metabasis) as a medicinal chemist and worked until 2009 with his last position as director of medicinal chemistry. Max then joined Merck as a Senior Investigator in the External Basic Research department, and then from 2011 to 2013, he was Director of External Medicinal Chemistry, Asia Lead, based in Shanghai facilitating Merck-CRO operations;
2013-2016, he was a Principle Scientist in the exploratory chemistry department at the Kenilworth site. In 2016 he joined Eli Lilly as Asia Head, BD and External Innovation for diabetes and CV research and worked until March 2018 before joining Qilu Pharmaceutical as VP, Global Head of BD and External Innovation with responsibilities for all BD and external collaborations globally including in-license, out-license and setting strategies for drug discovery and external collaborations. In June 2019, Max joined CSPC as corporate VP, President of CSPC Shanghai Research Institute, CEO of InnovStone Therapeutics, responsible for small molecule new drug discovery efforts. Max has extensive experiences in business development globally
and more than 25-years of experiences as a manager of drug discovery programs spanning from early (Target Selection and Validation, Lead Identification) to late (Lead Optimization and candidate selection) stages; led programs that advanced multiple compounds into human clinic trials (two completed Phase 2b POC studies); experiences in therapeutic areas including diabetes, dyslipidemia, hepatitis B and C, liver cancer, liver fibrosis,
anemia, viral and bacterial infections; extensive knowledge of Structure-based Drug Design, Medicinal Chemistry, Drug Delivery, Prodrugs, Liver targeting Strategies, Combinatorial, Heterocyclic and Nucleoside Chemistry; more than five years of managing drug discovery programs executed at various CROs. His research activities have led to 91 publications and 60 patents.
Chief Executive Officer and Co-Founder Eccogene
Dr. Zhou is Chief Executive Officer and co-founder of Eccogene. Prior to founding Eccogene, Dr. Zhou was the head of chemistry at Lilly China R&D Center, where he led project teams to achieve candidate selection milestones for diabetes and diabetic complications. Before joining Lilly in 2012, Dr. Zhou was investigator at GlaxoSmithKline working on drug discovery campaigns utilizing disruptive DEL technology. Dr. Zhou began his career at Tetraphase pharmaceutical, where he co-invented Eravacycline, an FDA approved drug for cIAI. He holds a Ph.D. in chemistry from Brandeis University and received a B.S. in life science from Fudan University.
BD & Licensing Manager
Roche Pharma Partnering
Dr. Dadong Li is currently a BD & Licensing Manager with Roche Pharma Partnering, based in Shanghai office. He is in charge of BD efforts in China across various therapeutic areas, from preclinical to late stage, and represent both Roche and Genentech. Prior to joining Roche, Dadong was a commercial officer with UK Department for International Trade at British Embassy in Beijing, where his responsibility is to facilitate UK China investment and trade in healthcare sector. Dadong also worked as a management consultant with PwC Management Consulting on strategy for healthcare companies and he has experience with Chinese Academy of Sciences as a junior scientist.
Dadong holds a Ph.D. in Chemistry from New York University, and a Bachelor degree in Materials Chemistry from Peking University.
Zhao-Kui (ZK) Wan
Fellow of the Royal Society of Chemistry, Founder & Chief Executive Officer
Dr. Wan is the founder and CEO of Lynk Pharmaceuticals, a VC supported biotech company focusing on oncology, auto-immune and inflammatory diseases. Dr. Wan earned his Ph.D. degree from Boston University, then conducted a postdoctoral research at Harvard University. Before starting Lynk Pharmaceuticals, Dr. Wan served as the Head of Chemistry at JNJ’s Asian Pacific Discovery Center with various cross-function responsibilities. He was one of the key leaders and played an instrumental role of building the Center from its earliest inception. Prior to JNJ, Dr. Wan had worked for Wyeth/later Pfizer for a dozen years and served as a group & project leader as well as a postdoc research advisor.
Dr. Wan has research experiences in multiple therapeutic areas and made significant contributions to the development a number preclinical candidates, clinical compounds and marketed products. Dr. Wan has more than 50 scientific publications in peer-reviewed journals and meeting abstracts; he also has close to 140 world and national patents. Dr. Wan won a number of awards and recognitions; he is an elected Fellow of the Royal Society of the Chemistry (2015), a winner of Young Industrial Investigators Award (ACS, 2008) and a steering committee member of Chemistry in Cancer Research of AACR (2017). Dr. Wan is a co-founder & a member of Board of Directors of Chinese BioMedical Association (CABA) and served as the President (2009- 2010). He is also a member of many prestigious professional organizations such as AACR, BayHelix and ACS.
Vice President, Analytical Operation Huahai Pharmaceutical
Dr. Min Li received his PhD in Organic Chemistry from Johns Hopkins University in 1991. Following a postdoctoral research in medicinal chemistry, he had worked for several multinational pharmaceutical companies with increasing responsibilities, including Roche, Merck & Co., Inc. Schering-Plough, and Merck again. Over the years, he has led technical teams of senior-level scientists for various analytical and pharmaceutical manufacturing process investigations and troubleshooting, impurity peak identification, study of drug degradation chemistry, analytical development, and support for new drug filing. Since September 2014, he became Vice President for Analytical Operation at Huahai Pharmaceutical, a leading Chinese pharmaceutical company with operations in both China and US. He also established the Center of Excellence for Modern Analytical Technologies (CEMAT), a technical core group created for solving the most challenging technical problems from pharmaceutical R&D to scale-up and commercial production at the company.
Dr. Li is a leading expert in drug degradation chemistry and he published a single-authored book, “Organic Chemistry of Drug Degradation” (by Royal Society of Chemistry) in 2012; the Chinese translation of this book was published in September 2019. He is the first/communicating author of more than 50 publications in organic, medicinal, bioconjugate, and analytical chemistry (including mass spectrometry). He is currently a member of the expert committee (Chemical Medicines 5) at United States Pharmacopoeia (USP) and a board member of Sino-American Pharmaceutical Professional Association (SAPA).
President & COO, Co-Founder Ascentage Pharma
Dr. Guo has been working in the healthcare industry since 1991, including ABC Laboratories, Pfizer, Ascenta Therapeutics, and Ascentage Pharma. At Pfizer (1995-2005) with various technical and management roles, Dr. Guo participated in many NCE drug R&D projects, several of which have successfully reached commercial stages. At Ascenta (2005-2009), Dr. Guo was the founding Vice President of Pharmaceutical Sciences & Manufacturing, and also General Manager of Ascenta (Shanghai) R&D Center which engaged in NCE drug R&D in China from 2005. Dr. Guo played an important role in Ascenta’s >$600M global out-licensing deals (i.e., with Sanofi-Aventis in 2010 and with Debio in 2011). Dr. Guo co-founded Ascentage Pharma in 2009, a globally positioned China innovative NCE drug R&D company, and currently serves as President & COO. The company has quickly built up a pipeline of 8 clinical-stage NCE projects along with several IND-enabling and discovery stage projects, covering oncology and anti-aging / anti-viral therapeutic areas through its apoptosis/PPI platform. During 2002-2005, Dr. Guo served as an Overseas Advisor for Beijing Zhongguangcun Biotech Park in China. He has been an adjunct professor, a faculty and graduate student adviser for the IPEM program at Peking University during 2007-2018. Dr. Guo served as an Independent Board Director at Porton Corporation (Chongqing, China) during 2012-2016, overseeing its successful IPO at Shengzhen Exchange, China, in 2014. As a co-founder and the founding Chairman, Dr. Guo has served on Board of Directors of SABPA (www.sabpa.org). Dr. Guo received his Ph.D. degree in Organic Chemistry at the University of California at San Diego; M.Sc. in Medicinal Chemistry at Institute of Materia Medica, Chinese Academy of Sciences; and B.S. in Chemistry at Peking Normal University.
Senior Vice President, CMC and Supply Chain Everest Medicines
Dr. Steven Hu currently is the Senior Vice President of Everest Medicines, being responsible for CMC and supply chain. Before he was the Senior Director of CMC in Roche Pharm Research and Development (pRED) Shanghai, heading process research and synthesis, analytical, preformulation and formulation development to support Roche China portfolio. Before joining Roche, Steven was the Director of New Product Development (NPD) of GSK China R&D, overseeing the whole drug product development life cycle from formulation development and optimization, process development and scale-up to technology transfer to commercial manufacturing. Steven had worked in Merck (West Point, PA) and J&J (Spring House, PA) respectively in the United States before coming back China in 2010.
Steven obtained his Ph.D. in Chemical Engineering from Brown University, USA, and then spent about two years at MIT as a Post-doctoral Research Fellow.
Senior Vice President of the Center of Project Process R&D AsymChem
Dr. Jim Li is chief executive officer of Sundia. In this role, Dr. Li is responsible for the oversight of all business divisions across the organization as well as formulating and driving key strategies for diversifying and growing the company. Dr. Li also leads the company’s executive committee, helping to drive Sundia’s overall global strategy.
Dr. Li has led a distinguished career in the pharmaceutical industry, having spent over 18 years at various companies including Henkel, Wyeth, Pfizer and Wuxi Apptec in the area of process research and medicinal chemistry. During his career, he was involved in numerous drug discovery programs such as COPD, asthma, Rheumatoid/osteoarthritis, and diabetes. Dr. Li has co-authored more than 60 research articles and patents.
Dr. Li received his Ph.D in Organic Chemistry from University of Central Lancashire UK followed by a postdoctoral fellow at the University of Chicago with Dr. Philip Eaton.
Chief Technology Officer EOC Pharma
Dr. Deepak Hegde completed his Doctorate in Biopharmaceutics and Pharmacokinetics from University of Mumbai in 1996. He also completed his Masters in Financial Management (M.F.M) from University of Mumbai in 2000.
He is currently working with EOC Pharma as Chief Technology Officer, responsible for development and manufacturing of new speciality anti cancer products for China. Prior to joining EOC, he was with GSK Shanghai, R & D China as Director, Global External Development & Supply, AsiaPacific, responsible for developing drug products for GSK global portfolio and for introduction of new products to China. Prior to this he worked with Wuxi AppTec as Vice President for Formulation Development. At WuXi Apptec, he was instrumental in setting up the Formulation Development Business as well as the formulation team, GMP facilities and systems which have since been approved by the EMA, USFDA and CFDA. While working with several multinational companies from US and Europe, he helped develop more than 150 NCE’s. He established several enabling technologies like Microdozing, Nanonization, Spray Drying, and Holt Melt Extrusion (HME) etc. at WuXi AppTec which helped customers expedite the First in Man (FIM) studies in US, Europe, Australia, Korea & China. Prior to joining WuXi AppTec in Shanghai, he has worked at several positions across Rhone Poulenc, Sandoz (A Novartis Group Company) and USV Ltd, a premier Indian Generic Company.
He has extensive experience in generic formulation development of solid and liquid oral and injectible formulations from a very early phase of development all the way to technical transfers to commercial manufacturing sites. At Sandoz, he worked on formulation development for the regulated markets like US and Europe and participated in technical transfers to commercial sites of Sandoz at Rolab in South Africa, and Novartis Bangladesh and Novartis Pakistan. Several generic products that he developed have since been registered and commercially launched in Europe, USA, South Africa and Asia.
He is a life member of the Indian Pharmaceutical Association. He has two US patents, five PCT and US patent applications and several National and International publications to his credit.
Executive Director and CMC Head Shanghai HaiHe Pharmaceutical Co.,Ltd.
Dr. Ma obtained his Ph.D. from Shanghai Jiao Tong University, and went on with organocatalyst research in NTU as a postdoctor. He has 10 more years of experience of drug R&D and management, focus on CMC. Dr. Ma joined HaiHe in mid of 2016, and set up CMC department. He oversees CMC development and DS/DP manufacturing for all HaiHe’s pipeline products
Chief Technology Officer PharmaBlock
Dr. Shijie Zhang, currently serving as Chief Technology Officer at PharmaBlock, is leading initiative to extend the team’s competence in process development and manufacturing to support clients’ late phase and commercial programs. Dr. Shijie Zhang has 20 years of combined experience in medicinal chemistry, process chemistry, and API manufacturing. Before joining PharmaBlock, he led the CMC API team at Agios for the two FDA-approved therapies (Idhifa®, Tibsovo®), by managing and overseeing API development programs and manufacturing activities spanning from preclinical stage to commercial stage, and preparing API sections of regulatory filing documents, including IND, IMPD, NDA, and briefing documents.
Vice President, Discovery and Early development Antengene
Vice President and CMC Head Dizal Pharmaceutical
Shih-Ying joined Dizal at January 2019 as the CMC head for API and drug products development, Clinical manufacturing, and supply chain management. Before coming back to Shanghai, he has worked in Pharmaceutical Development in Bristol-Myers Squibb at New Brunswick New Jersey for 13 years. During the tenure in BMS, he has worked on more than 40 different new chemical entities including Brivanib and Cabozentinib in the oncology area, contributed more than 5 NDA dossiers preparation, especially as the author of the Module 3 QbD sections for Onglyza, which was approved as the first QbD-based NDA filings. Other approved NDAs that he has participated including Sprycel, Kombiglyza, Reyataz, and Daclatasvir. After coming back to Shanghai to join Hutchison MediPharma as the Executive Director of Formulation at 2015, he has contributed to Fruquintinib NDA approval in CFDA. He has also served as the CMC project lead to collaborate with AstraZeneca for the joint global development of Savolitib. In Hutchison he successfully finished two bio-equivalency studies to facilitate formulation changes during pivotal trials.
Senior Vice President, CMC Hua Medicine
Dr. Jin She is Senior Vice President of Chemistry Manufacturing & Control department at Hua Medicine (Shanghai) Ltd. Dr. She has over 16 years’ of experience in the biotechnology and pharmaceutical industry. Prior to Hua Medicine, he worked at MSD R&D Center (China) as Director of Process Chemistry, and Roche R&D Center (China) as Head of Process Research & Synthesis. Before returning back to China from the US, he worked at Inspire Pharmaceuticals Inc. as Sr. Research Scientist and team leader of Process Research. Dr. She has also been an Industrial Advisor for Engineering Master Program at East China Science & Technology University for the last 8 years. Dr. She Received his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill. He obtained his BS and MS degrees in chemistry from Beijing University.s
Vice President, Head of CMC Laekna Therapeutics
Dr. Feng is currently Vice President and head of CMC of Laekna Therapeutics. He oversees CMC development and manufacturing for all Laekna’s pipeline products. Dr. Feng has more than sixteen years’ experience in new drug research and development including preclinical development, early phase and late phase product development, clinical manufacturing and process validation towards commercialization. He has led the technical transfer, clinical manufacturing, and process validation of various products, including successful approval and commercial launch of Niraparib in China. Prior to Laekna, Dr. Feng has held various management roles in Zai Lab, WuXi Apptec, and Schering Plough in US. Dr. Feng received his PhD from Purdue University.
Director, Integrated CMC New Product Program Sanofi
Dr. Zhixuan Wang is as project CMC operation management role in Integrated CMC New Product Program department at Sanofi China. She Holds Master degree from Peking University and Ph.D from Shenyang Pharmaceutical University. She started her career in drug product development in North China Pharmaceutical Group Corporation. In 2006 she joined in Chinese Academy of Sciences and working on transdermal drug delivery system research work. In 2007, she joined Novartis China as Senior Scientist in Chemical and Pharmaceutical Profiling, Novartis Institutes for Biomedical Research Co., Ltd, and followed GSK R&D China in 2011. Zhixuan has worked on a wide variety of Discovery & Development projects, her role includes compound developability assessment, physical form selection, formulation development, drug product manufacture and clinical supply, CTA/NDA submission and new product launch. She is also involved in Innovative drug delivery system research and development work. Dr. Wang has published ~ 30 papers and patents. Zhixuan has contributed chapters to “Liposome Technology” and “Novel technologies of microencapsulation and the application in DDS”.